Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
4Customers
1Debt Items
20Related Chains
Source-Backed Evidence Depth
Curanex Pharmaceuticals Inc (CURX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
2Distinct source URLs
4High confidence
0.774Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Curanex Pharmaceuticals Inc Suppliers
Ticker
Name
Confidence
Evidence
DURAVIVA
DURAVIVA
92%
In January 2025, Duraviva also assigned its office lease to the Company.
DURAVIVA-PHARMA-INC
DURAVIVA-PHARMA-INC
90%
On June 17, 2024, we entered into the Asset Purchase Agreement with Duraviva Pharma Inc (“Duraviva”), a New York corporation, pursuant to which, on the same date, we acquired from Duraviva four (4) p…
Reciprocal relationship from LGND graph: Reciprocal relationship from CURX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from CURX graph: Reciprocal relationship from LGND g…
Reciprocal relationship from LGNZZ graph: Reciprocal relationship from CURX graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from CURX graph: Reciprocal relationship from LGNZ…
Reciprocal relationship from LGND graph: Reciprocal relationship from CURX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from CURX graph: Reciprocal relationship from LGND g…
Reciprocal relationship from LGNZZ graph: expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for E…
DURAVIVA-PHARMA-INC
DURAVIVA-PHARMA-INC
62%
es related to fair value measurement and developments. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction betwee…
EMERGING-GROWTH-COMPANY
EMERGING-GROWTH-COMPANY
62%
e restrictions and trade barriers, renegotiation of international trade agreements or further escalation of trade tension, sanctions and export controls which also increase volatility in the global e…
Curanex Pharmaceuticals Inc Debt Obligations
Instrument
Description
Confidence
Evidence
CURX-DEBT
Debt stack $476,452
90%
Market cache reports total debt of $476,452.
Curanex Pharmaceuticals Inc Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Curanex Pharmaceuticals Inc.
Curanex Pharmaceuticals Inc Ownership
Holder
Name
Confidence
Evidence
CURX-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC
GEODE CAPITAL MANAGEMENT, LLC
90%
13F overlay lists GEODE CAPITAL MANAGEMENT, LLC as top holder; 9 tracked holders.
